Organon & Co Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
3.1%projected annual EPS growth
Analyst Coverage
4analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Transaction Closing (Sun Pharma Merger) | 31 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly1.5B
Adjusted EBITDA Annually1.9B
Watch Items
- Sun Pharma Acquisition Regulatory and Shareholder ApprovalsTrigger: Failure to obtain antitrust clearances or shareholder majority voteAction: Re-evaluate standalone valuation, debt refinancing risks, and potential downside to pre-rumor stock levels (~$9.00)
- Net Leverage RatioTrigger: Net leverage remaining above 4.0x adjusted EBITDAAction: Monitor cash allocation priorities, dividend policy adjustments, and progress on non-core asset divestitures
Research as of 20 Jun 2026